NovoCodex Biopharmaceuticals
Engaged in the business of genetic engineering, and cell culture, among others
About NovoCodex Biopharmaceuticals
NovoCodex Biopharmaceuticals Co., Ltd. is a biopharmaceutical company established in January 2017, operating as a subsidiary of the publicly listed Zhejiang Medicine Co., Ltd. Located in Shaoxing, China, the firm concentrates on the research, development, and manufacturing of innovative biological drugs, primarily for oncology. The company's business model revolves around in-house drug development and strategic collaborations to bring new cancer therapies to market, targeting unmet clinical needs.
NovoCodex possesses end-to-end capabilities, from genetic engineering, cell culture, and toxin synthesis to ADC (Antibody-Drug Conjugate) coupling and preclinical and clinical research. A core technological strength lies in its pioneering use of non-natural amino acids for site-specific protein modification. This technique allows for the precise attachment of toxins to monoclonal antibodies, a key process in creating next-generation ADC drugs. The company has established R&D centers and manufacturing facilities to support its pipeline, including a production base in Guangzhou capable of producing at a commercial scale.
The company's main products are antibody-drug conjugates designed for targeted cancer therapy. A notable product in its pipeline is ARX788 (also referred to as NCB001), an anti-HER2 ADC for treating HER2-positive recurrent breast and gastric cancers. This drug is currently undergoing clinical trials. Another significant pipeline candidate is ARX305, an anti-CD70 ADC developed for CD70-positive cancers like Renal Cell Carcinoma and Multiple Myeloma. NovoCodex's revenue is generated through product sales, licensing agreements, and milestone payments from its collaboration partners. The company collaborates with international biopharmaceutical firms, such as Ambrx, to co-develop and commercialize its assets, sharing responsibilities for different geographical markets. For instance, in its partnership with Ambrx for ARX305, NovoCodex handles development and commercialization in China, while Ambrx is responsible for markets outside of China.
Since its founding, NovoCodex has secured significant funding, including a Series A round of $61.5M and a Series B round of $59.7M, bringing its total raised capital to over $123M from investors like Lilly Asia Ventures, Matrix Partners, and CS Capital. The company has received numerous accolades, including being named a science and technology-based SME in Zhejiang Province.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 20.7/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Mar 2026 | $85M | $520M | Puhua Capital · Prosperity Investment · CITIC Medical & Heath Group · Zhejiang Xinhai Biotechnology | ↗ |
| SERIES BOther financing | Jul 2022 | $55M | $220M | SDIC Capital · Runtu Touzi | ↗ |
Growth signals
Latest recorded traffic for NovoCodex Biopharmaceuticals is 1.3K monthly website visits, up 251.4% over the last three months.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
NovoCodex Biopharmaceuticals in the Huangpu ecosystem
The NovoCodex Biopharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
Matrix Partners China- HIHangzhou Sanhua Hongdao Investment
Lilly Asia Ventures- CCCMG-SDIC Capital
SDIC Capital- RTRuntu Touzi
Series B and later5 investors entered at this stage
- PCPuhua Capital
Prosperity Investment
CITIC Medical & Heath Group- ZBZhejiang Xinhai Biotechnology
Dongguan Financial Holdings
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about NovoCodex Biopharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See NovoCodex Biopharmaceuticals’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









